Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma
- 18 October 2004
- journal article
- research article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 41 (6), 1008-1016
- https://doi.org/10.1016/j.jhep.2004.08.024
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Hepatocellular carcinomaThe Lancet, 2003
- The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An UpdateAnnals of Internal Medicine, 2003
- Hepatocyte growth factor, transforming growth factor α, and their receptors as combined markers of prognosis in hepatocellular carcinomaMolecular Carcinogenesis, 2003
- Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?The Oncologist, 2002
- Why the Epidermal Growth Factor Receptor? The Rationale for Cancer TherapyThe Oncologist, 2002
- International trends and patterns of primary liver cancerInternational Journal of Cancer, 2001
- Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United StatesHepatology, 2001
- Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinomaLiver International, 1997
- Quantitative Relationship Between Transforming Growth Factor-Alpha and Hepatic Focal Phenotype and Progression in Female Mouse LiverToxicologic Pathology, 1997
- Carcinogen-induced alteration in liver epidermal growth factor receptor distribution during the promotion stage of hepatocarcinogenesis in ratCancer Letters, 1997